In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
In this study of nine clinical isolates obtained from integrase inhibitor-naïve HIV-2-infected patients, the median EC₅₀ value for the new integrase inhibitor S/GSK1349572 was 0.8 nM (range 0.2-1.4), and is similar to HIV-1 reference strains. We found a seven-, 13- and 18-fold increase in EC₅₀ values to S/GSK1349572 for the HIV-2 double (T97A + Y143C; G140S + Q148R) and triple (G140T + Q148R + N155H) mutants, respectively, obtained from two raltegravir-experienced patients.
Charpentier
Charlotte
C
Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude Bernard, Université Paris-Diderot, France.
Larrouy
Lucile
L
Collin
Gilles
G
Damond
Florence
F
Matheron
Sophie
S
Chêne
Geneviève
G
Nie
Ting
T
Schinazi
Raymond
R
Brun-Vézinet
Françoise
F
Descamps
Diane
D
D024882:Drug Resistance, Viral / Q000187:drug effects / Q000235:genetics*; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics*; D019428:HIV Integrase Inhibitors / Q000494:pharmacology*; D015498:HIV-2 / Q000187:drug effects / Q000302:isolation & purification*; D006801:Humans; D009154:Mutation
D019428:HIV Integrase Inhibitors